Commure: a $7 billion healthcare-AI operating system
From a 2017 General Catalyst incubation to a $7 billion company by 2026 — built on the 2023 Athelas merger, a string of acquisitions, and a clear run at an IPO. Here's the one-page story.
The app, in plain English
One clinician-facing app and back-office layer that takes the busywork out of care — so doctors spend less time on screens and more with patients.
Writes the visit note for you
Listens to the doctor–patient conversation and drafts the clinical note automatically.
Built on the Augmedix acquisition, the ambient scribe turns natural speech into a structured note in the EHR — cutting hours of after-hours "pajama time" charting.
Gets the clinic paid, faster
Automates billing, coding and insurance claims so practices collect more, sooner.
The Athelas-originated RCM engine processes tens of billions of dollars in healthcare payments a year and is a core revenue line for Commure.
Watches patients at home
Tracks vitals between visits and flags problems before they become emergencies.
Remote patient monitoring (RPM) feeds at-home readings back to the care team, supporting chronic-condition management and earlier intervention.
Protects hospital staff
Wearable badges let nurses silently call for help if a patient encounter turns violent.
Strongline is a discreet staff-safety system for hospitals — one of Commure's enterprise products deployed across large health systems alongside its mobile EHR.
Three people, one trajectory
Tanay Tandon
Co-founded Athelas in 2016 as a Stanford CS student; now CEO of Commure and the driver of its M&A.
A Google Science Fair and Intel STS finalist (presented at the White House) by 2015. Interned at Wit.ai (→ Facebook) and MetaMind (→ Salesforce). Athelas began as a smartphone blood-diagnostic system, then pivoted to RCM and remote-monitoring software.
By the October 2023 merger, Athelas had raised $136M and was valued at $1.5B. Tandon says Commure expects to be IPO-ready within two years of mid-2025.
Deepika Bodapati
Co-founded Athelas with Tandon in 2016, dropping out of college; now COO of Commure.
Research background at Stanford's Multimodality Molecular Imaging Lab (2010–2015) and NASA Ames (2008). Named to Inc.'s 2026 Female Founders 500. Her thesis: healthcare's admin and care-delivery problems matter as much as diagnostics.
Hemant Taneja
CEO of General Catalyst, who incubated Commure inside the VC firm in 2017; now Executive Chair.
The GC-backed origin means General Catalyst has been both investor and co-creator throughout — a structural strength, and a concentration risk.
The Athelas–Commure merger
October 2023 — the deal that made Commure what it is today.
The deal in one line
Athelas folded into Commure at a $6B valuation; its CEO and COO took the top seats and kept the Commure name.
- Fresh capital: General Catalyst put in a new $70M at $6B for the combined entity.
- Terms: the Athelas-side financials were not disclosed; Athelas had grown 500%+ in three years.
- After close: $100M+ ARR run-rate, HCA Healthcare joined the board — then a November 2023 layoff round of "redundant" staff, despite an earlier pledge to hire aggressively.
Seed to $7 billion
From a $2M seed in 2017 to a $7B valuation in 2026 — open the table for the full curve.
| Date | Event | Valuation | Raised |
|---|---|---|---|
| Sep 2017 | Commure Seed | — | $2M |
| Apr 2019 | Commure Series B | — | $27M |
| May 2026 | Latest Round | $7.0B | $70M |
| Jan 2018 | Commure Series A | — | $10M |
| Nov 2020 | Commure Series C | $3.5B | $210M |
| Sep 2021 | Commure Series D | $3.5B | $500M |
| Jan 2022 | Athelas Series B | $1.5B | undisclosed |
| Oct 2023 | Athelas + Commure Merger | $6.0B | $70M (GC) |
| Jun 2025 | Series F / Growth | $6.0B | $200M |
Total raised to date: roughly $750M–$966M (sources vary on debt and non-dilutive instruments). The $3.5B Series C/D valuation was high for a not-yet-productised platform — driven by GC's conviction and the healthcare-tech bull market.
Commure as an acquirer
It bought its way to a full-stack platform. Tap a card for the detail.
Augmedix
Ambient-AI medical scribe (Nasdaq: AUGX), taken private at $2.35/share.
Closed October 2024 after stockholder approval — added the AI scribe product and a big provider base.
Memora Health
Digital care-navigation platform out of Harvard Innovation Labs.
Strengthened patient engagement; with Augmedix, put Commure on track to power 3M+ physician appointments with AI.
The business model
Revenue & growth
~$105M ARR (est. March 2024), up 150% YoY — and ARR has doubled three years running.
Two segments: Athelas products (RCM + remote monitoring) and Commure enterprise (clinical docs, Strongline staff safety, mobile EHR). It runs across 500+ orgs and 3,000+ sites, integrating 60+ EHRs; enterprise contracts start at $1M+/yr. Cash-flow positive targeted by end of 2026, IPO in 2027.
By the numbers
- ~$105M ARR — est. March 2024
- 150% YoY — revenue growth
- 3,000+ — sites of care
- 60+ — EHR systems integrated
- 3M+ — AI-powered appointments (target)
"The new healthcare-AI playbook: merge, acquire, integrate — then turn an operating system into an IPO."Commure · 2017 → 2027
The syndicate & the IPO road
IPO outlook
Plans confirmed in June 2025: cash-flow positive by end of 2026, IPO filing in 2027.
Commure may raise a pre-IPO round and has floated a tender offer for early liquidity. It already trades on the Nasdaq Private Market — at $7B, among the most valuable private US healthcare-tech companies.
Key risks
- Integration complexity: three acquisitions to bolt together onto change-resistant health systems.
- GC concentration: General Catalyst is founder, repeat investor and anchor — strength and dependency.
- AI commoditisation: ambient scribing is commoditising vs. Microsoft Nuance and pure-plays.
- Post-merger layoffs: the Nov 2023 cuts signalled execution friction.
- Multiple compression: $7B vs. ~$200M ARR needs sustained 100%+ growth to justify.
References
- "Indian-origin founders' healthcare AI firm Commure raises $70 mn."
- "Athelas + Commure: Merging to Create a $6B Healthcare Infrastructure Company" — Tanay Tandon.
- "Commure Raises $70M to Expand AI Healthcare Operations Platform."
- "2 General Catalyst health-data startups joining forces to create a $6B AI colossus."
- "Healthcare AI firm Commure valued at $7 billion, raises $70 million."
- Tanay Tandon & Deepika Bodapati — LinkedIn; "Athelas Deal Terms."
- "Commure raises $200M in growth financing from General Catalyst."
- "Augmedix acquired by Commure for $139M" — Healthcare IT News.
- "Commure acquires patient navigation platform Memora Health."
- Sacra — "Commure at $105M ARR" & "Valuation & Funding History."
- "A $6B healthcare-AI startup cut staff after pledging to hire 'aggressively'."
- SiliconANGLE; Dealroom.co; Nasdaq Private Market.
Field notes, when they're worth reading
Deep-research breakdowns like this on the companies reshaping AI, healthcare and the Gulf economy — one note a week, no spam.
Subscribe to the newsletter →Compiled from public reports & industry analysis. Figures approximate; sources vary. Not affiliated with Commure, Inc.